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Background. The effect of beta blockers on myocardial blood flow (MBF) under vasodi-
lators has been studied in several SPECT and PET myocardial perfusion imaging (MPI) studies
with divergent results. The present study evaluated the effect of a beta blocker withdrawal on
quantitative adenosine MBF and on MPI results.
Methods. Twenty patients with beta blockers and CAD history were studied with quan-
titative adenosine N-13 ammonia PET. The first study was performed under complete
medication and the second after beta blocker withdrawal. The PET studies were independently
read with respect to MPI result and clinical decision making.
Results. Global MBF showed an increase from 180.2 ± 59.9 to 193.6 ± 60.8 mLminute21/
100 g (P 5 .02) after beta blocker withdrawal. The segmental perfusion values were closely
correlated (R2 5 0.82) over the entire range of perfusion values. An essentially different
interpretation after beta blocker discontinuation was found in two cases (10%).
Conclusion. A beta blocker withdrawal induces an increase in adenosine MBF. In the
majority of cases, MPI interpretation and decision making are independent of beta blocker
intake. If a temporary beta blocker withdrawal before MPI is not possible or was not realized
by the patient, it is appropriate to perform adenosine stress testing without loss of the essential
MPI result. (J Nucl Cardiol 2014;21:1223–9.)
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INTRODUCTION
Myocardial perfusion imaging (MPI) is an effective
noninvasive modality for diagnosing coronary artery
disease (CAD) and yields valuable information con-
cerning risk, prognosis and therapeutical
management.1,2 Ergometry is the stress test of choice
and most frequently applied. However, the proportion of
vasodilator stress tests with adenosine, dipyridamole and
recently with regadenoson is growing.3 All vasodilators
increase MBF to comparable levels.4,5 Adenosine and
regadenoson through direct coronary vasodilation via
adenosine A2A receptors, and dipyridamole indirectly
through a prolonged action of endogenous adenosine by
an inhibition of adenosine deaminase.6,7
Despite maximal vasodilation by pharmacologic vaso-
dilators, an interaction of cardiac medications such as beta
blockers, calcium blockers, and nitrates has been suggested
in several studies.8-12 Current guidelines recommend tem-
porarily discontinuing beta blockers before stress testing.13,14
In clinical routine a temporary beta blocker with-
drawal before stress perfusion testing is sometimes not
possible due to complications, contraindications, a tight
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clinical schedule, or because a patient simply forgot to
withhold the medication. Thus, the question arises of
whether MPI under vasodilators is affected by beta
blockers or their withdrawal at all.
The results of some recent studies addressing this
issue are contradictory:
Two retrospective analyses reported a similar sen-
sitivity and specificity between patients with and without
beta blockers and no effect of beta blocker therapy on
extent, severity, and perfusion defects.15,16 On the other
hand, a significant impact of beta blockers on adenosine
MPI has been demonstrated in a prospective study.12 All
the cited studies related to MPI in SPECT technique.
The present prospective study was designed to
determine the absolute effect of a temporary withdrawal
of beta blockers on quantitative adenosine MBF with
N-13 ammonia PET and to estimate its impact on the
results and the interpretation of PET MPI.
METHODS
Patient Population and Study Protocol
We studied a total of 20 patients (68 ± 11 years, 15 men)
with CAD and typical dosage regimens of cardiac drugs,
including long-term beta blocker medication (Table 1). Exclu-
sion criteria were contraindications for adenosine stress testing
and for discontinuation of beta blocker therapy.
The first imaging procedure was performed under complete
medication and consisted of a quantitative adenosine N-13
ammonia PET scan and, if necessary, of an N-13 ammonia rest
scan. A second quantitative adenosine N-13 ammonia PET scan,
which represented the actual study acquisition, was performed
after withdrawal of the individual beta blocker for at least four
half-lives. The other cardiac medication remained unchanged.
The study protocol was approved by the local ethics
committee of the Ruhr-University Bochum (Reg. No. 42/2011)
and the German Federal Office for Radiation Protection
(Bundesamt fu¨r Strahlenschutz, Z5-22463/2-2011-014). All
patients gave their written informed consent.
Adenosine Stress Testing and Image
Acquisition
All patients were investigated with a Biograph mCT
(Siemens, Erlangen, Germany). Directly before the PET
acquisition a low dose CT scan for attenuation correction
was performed. In this paper, the term PET is used instead of
PET-CT since we only refer to the PET measurements.
Adenosine was infused intravenously at a constant rate of
0.14 mgkg-1minute-1 over 6 minutes.
Two minutes after the onset of the adenosine infusion,
about 600 MBq N-13 ammonia was injected as an intravenous
bolus. Image acquisition over 15 minutes was started simul-
taneously with the bolus injection. Data were recorded in list
mode. A consecutive set of 20 frames (12 frames 5 seconds, 5
frames 30 seconds, 2 frames 120 seconds, 1 frame 450 sec-
onds) was reconstructed for quantification of perfusion. The
last 5 minutes of the emission scan were used for ECG-gated
reconstruction with 12 gates.
Adenosine Side Effects
The commonest adenosine side effects (flush, headache,
thoracic pressure, angina pectoris, and dyspnea) were assessed
with a four-category score (0—no symptom, 1—mild,
2—moderate, 3—severe symptoms) in each case and finally
summed to a global side-effect score with a range from 0 to 15.
A 12-channel ECG was started 1 minute before the adenosine
infusion up to the end of the emission scan. Arrhythmias and
ST-segment depressions were recorded.
Quantitative Analysis and Scoring of PET
Perfusion Data
Quantification of the N-13 ammonia scans was based on
an irreversible 2-compartment model which was implemented
Table 1. Patient characteristics
%
Age 68 ± 11
Gender 15m, 5f 75/25
Cardiac risk factors
Diabetes mellitus 15 75
Hyperlipidemia 17 85
Hypertension 18 90









ACE inhibitors 12 60
AT1-receptor antagonists 4 20
Central receptor blockers 3 15
Diuretics 13 65





Prior infarction 3 15
Prior PTCA 14 70
Prior CABG 5 25
Cardiomyopathy 2 10
Arrhythmia 1 5
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in MATLAB.17 The model was fitted to the dynamic data using
the linear least squares approach first proposed by Blomqvist.18
Corrections for fractional blood volume, limited recovery due
to partial volume effects and spillover activity from left
ventricular blood pool to tissue were performed as described
elsewhere.19 The implementation of the fitting procedure was
validated by using a representative measured arterial input
function and the analytical solution of the described
2-compartment model, including all correction terms for
generation of simulated tissue response functions at different
assumed flow levels. A validation in humans was performed by
the argon inert gas technique.20 The quantification procedure
delivered 20-segment parametric polarmaps of MBF. Seg-
ments with a fractional blood volume[0.5 were excluded from
further analysis. This value was taken as an empirical cut-off
indicating failure to correctly delineate the center of the
myocardial wall. Such large values are only explainable by
massive spillover from the ventricle and occurred in most
cases in the basal segments of the septum. Furthermore,
segments with a resting MBF \ 50 mLminute-1/100 g were
regarded as infarcted and also excluded from the analysis. A
total of ten segments in three patients were rejected from
analysis for this particular reason. Global perfusion was
calculated as the average of all myocardial segments.
Hemodynamic Parameters
During the stress phase, heart rate and blood pressure
were recorded every 2 minutes, starting with the onset of the
adenosine infusion until completion of the infusion after
6 minutes. Mean arterial blood pressure was calculated from
the average values of all 4-time points and mCR as mean
arterial blood pressure/global perfusion. To account for
changes in MBF by different cardiac work at the time of the
two individual scans, global MBF was normalized to a rate-
pressure product (RPP) of 10,000 mm Hgminute-1. The
normalization was achieved by multiplying the global MBF
value by the ratio of an RPP of 10,000 mm Hgminute-1 and
the average RPP during the individual adenosine stress test.
PET Study Interpretation
The PET study sets were read by two nuclear medicine
physicians with expertise in nuclear cardiology and unaware of
the status of beta blocker intake. For the interpretation and the
management recommendation, the readers considered the
quantitative polarmaps with tables of absolute segmental
MBF under adenosine, segmental fractional blood volume
for quality control, clinical information and, if performed, the
rest MBF study.
The graduation of MBF abnormalities included both extent
and severity of disturbances. Based on routine clinical judgment,
they were classified as normal, mildly, moderately, and severely
abnormal. A MBF [ 200 mLminute-1/100 g was regarded as
normal. The clinical interpretation with patient management
recommendation were ‘‘risk modification’’ in normal, ‘‘medical
therapy’’ in mild, and ‘‘further diagnosis (CT or invasive
angiography)’’ in moderate and severe results.21
In special cases where an angiography had been per-
formed shortly before the studies or prescan data were
available, the management recommendation was adjusted
accordingly.
Statistical Analysis
For the sample size estimation, a power of 90% and a
significance criterion of 0.05 were chosen. The minimum
expected differences between the two means and the standard
deviation were estimated to 10 mLminute-1/100 g each.
Accordingly, about 20 patients had to be enrolled in the study.22
Data are given as mean value ± standard deviation. In the
first step, the paired parameters were tested for the normal
distribution with the Kolmogorov-Smirnov test. As all param-
eters were normally distributed, post hoc comparisons were
performed with a paired t test. Differences were considered
statistically significant at values \0.05 (two-sided). Pearson’s
correlation coefficient was used to assess the interrelationship
between absolute MBF with and without beta blocker use. For
the analyses, the statistical software package IBM SPSS
(version 20) was used.
RESULTS
Clinical Characteristics, Hemodynamic
Parameters, and Ventricular Function
Table 1 summarizes the characteristics of the study
patients. Nineteen patients (95%) took cardioselective
beta blockers and one patient (5%) the non cardioselec-
tive beta blocker carvedilol.
The beta blocker withdrawal was well tolerated by
all patients without exacerbation of angina symptoms.
Hemodynamic parameters are given in Table 2
(upper third). Mean systolic and mean diastolic blood
pressure during adenosine were nearly identical (P = .77
and P = .78) with and without beta blocker. Mean heart
rate and mean RPP during adenosine significantly
increased after beta blocker withdrawal by 17% ± 17%
(P \ .001) and 19% ± 23% (P = .004), respectively.
The left-ventricular function parameters showed no
change (Table 2, middle third).
Adenosine Side Effects and ECG
The symptom scores during adenosine infusion did
not differ significantly, they were 3.7 ± 1.9 with and
3.4 ± 1.6 (P = .43) without beta blocker.
ECG changes with ST depressions[0.1 mV occur-
red in one patient with beta blocker. This patient
exhibited more pronounced ST alterations during the
2nd scan. Another patient without ST changes with beta
blocker demonstrated ST depressions under adenosine
after beta blocker discontinuation.
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Quantitative Analysis
The data are listed in Table 2, lower third. Global
MBF showed a significant increase by 8% ± 10%
(P = .002) after beta blocker withdrawal. The individual
data are depicted in Figure 1. All but three patients had a
lower global MBF without beta blocker than with. The
segmental MBF values (Figure 2) demonstrated a strong
correlation over the entire range of perfusion values. The
average effect was a slight perfusion shift of about 10-
15 mLminute-1/100 g in the range of 100-300 mLmin-
ute-1/100 g. The mCR under adenosine declined by
5% ± 11% (P = .038) and the normalized RPP by
11% ± 21% (P = .032) after beta blocker discontinuation.
PET Study Interpretation
The interpretation of the PET studies with the clinical
management recommendation is depicted in Figure 3.
Independent of beta blocker intake, all patients with normal
and severe MBF abnormalities experienced no change in
study interpretation. In four cases, the study interpretation
differed by one category. This was in three cases a
downstaging, due to the higher MBF after beta-blocker
withdrawal and in only one case an upstaging. In two of the
four cases an essentially different MPI interpretation, with a
change from medical therapy recommendation to angiog-
raphy or vice versa, was observed. One of these two patients
had mild and the other moderate MBF abnormalities.
DISCUSSION
Effect of Beta Blocker Withdrawal on
Myocardial Perfusion
Beta blockers are one of the most frequent medi-
cations in the treatment and management of patients
with hypertension and CAD.
The entire mode of action is multiple and still
incompletely understood.23 Most important in the con-
text of this paper are the negative chronotropic and
inotropic effects which decrease cardiac workload and
oxygen consumption during exercise stress, and corre-
spondingly MBF. As a consequence, MBF differences
required to detect flow-limiting stenosis can be dimin-
ished, and thus the diagnostic accuracy of MPI.24,25
Guidelines therefore recommend a discontinuation of
beta blockers for several half-lives before MPI.13,14
Pathophysiologically, the impact of beta blockers
on exercise or dobutamine stress testing is evident.24
Their effect on vasodilator stress testing should be
minimal since vasodilation occurs uncoupled from
oxygen demand. The results of quantitative PET studies
addressing this issue, however, are inconsistent:
Table 2. Hemodynamic response under adenosine, perfusion, and left-ventricular function
With beta blocker Without beta blocker P
Heart rate (BPM) 69.7 ± 12.1 80.3 ± 10.9 \.001
Systolic blood pressure (mm Hg) 117.3 ± 19.9 118.2 ± 19.3 .77
Diastolic blood pressure (mm Hg) 55.8 ± 9.9 56.1 ± 8.8 .79
Rate-pressure product (mm Hgminute-1) 8,159.5 ± 1,943.0 9,487.0 ± 2,025.4 .004
EDV (mL) 164.5 ± 36.5 162.6 ± 43.9 .59
ESV (mL) 61.8 ± 12.6 62.9 ± 16.0 .64
EF (%) 39.4 ± 10.7 40.6 ± 0.29 .29
Global myocardial perfusion (mLminute-1/100 g) 180.2 ± 59.9 193.6 ± 60.8 .002
Minimal coronary resistance (mmHg(mLminute-1/
100 g)-1)
0.49 ± 0.19 0.45 ± 0.16 .038












Figure 1. Myocardial perfusion under adenosine with and
without beta blocker.
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(1) In 10 healthy volunteers, perfusion under
dipyridamole without metoprolol was significantly
lower than with (186 ± 27 vs 234 ± 45 mgminute-1/
100 g).26 (2) In 36 CAD patients with adenosine PET,
no effect of metoprolol and carvedilol on global MBF
was found, but a significant shift of hyperemic MBF in
stenosis-dependent segments.27 (3) An increase in
hyperemic MBF of about 20% was demonstrated in 14
male CAD patients when metoprolol had been
withheld.11
In the present study, MBF in CAD patients
increased by about 8% over the entire range of measured
MBF values after beta blocker discontinuation. As
systolic and diastolic blood pressures were not different
with and without beta blockade, the increase in heart
rate remains as one factor of the MBF shift. In this way,
heart rate also indirectly contributes to the decrease in
mCR. Of note, heart rate is not the only factor because
RPP normalized MBF did not remain constant, but
decreased under adenosine. Under resting conditions,
the relationship between RPP and MBF was not affected
by beta blockade, as reported in former studies.11,26
Therefore, it is to conclude that further interfering
factors are involved in the regulation of MBF under
adenosine and beta blockade.
The potential mechanisms are multiple and have
been discussed in previous papers in detail: (1) longer
diastolic perfusion of the subendothelial layer due to
lower heart rate,11,26 (2) suppression of sympathetic
regulation of coronary arteries,28 and (3) increase in
collateral vessel resistance with fewer poststenotic steal
effects.29
Changes of the ventricular function parameters
EDV and EF were not observed in the present study
and can be excluded as causative factors.
However, it needs to be considered that the hyper-
emic MBF response after beta blocker withdrawal was
not uniform in all patients. Three patients (15%) did not
exhibit an increase, but a decrease in MBF. This
observation supports the aforementioned complex and,
according to previous studies, non-uniform interaction
between beta blockers and vasodilator MBF.11,26,27
PET Study Interpretation
Against this background, the question arises of
whether, and to what extent, diagnostic accuracy and
MPI management recommendation are affected by beta
blockers or their withdrawal.
The first issue has been addressed in several studies.
Some of them revealed a reduced sensitivity for the
detection of flow-limiting CAD.9,10,12 Sharir et al9
studied 21 patients with and without their individual
antianginal medication (21 patients with calcium antag-
onists, 19 with nitrates, and 8 with beta blockers) and
found a sensitivity of 92% without and 62% with
medication. Taillefer et al considered placebo vs meto-
prolol with dipyridamole MPI. Sensitivity decreased
from 85.7% with placebo to 71.4% with metoprolol. Of
note, 17 patients out of 21 had similar results with
placebo and metoprolol, but only four differed.10 Reyes
et al12 demonstrated in 45 patients a small but significant
reduction in the extent and severity of perfusion abnor-
malities under adenosine, and a decrease in sensitivity
from 76% to 58% under beta blockade. Yoon et al15
retrospectively studied 555 patients with MPI and
angiography and found similar sensitivities between
those with and without beta blockers and similar
summed stress scores. Likewise, Lakkireddy et al16
(158 patients, 48 with beta blocker withdrawal) revealed
Figure 2. Segmental perfusion with and without beta blocker.
* no progression: refers to one patient with a prescan three years ago and known 
angiography. No change in interpretation with and without beta blocker.
# consider intervention: refers to two patients with angiography prior to the PET 
scans
Figure 3. Interpretation of the PET studies and management
recommendation.
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no impact of beta blockade on extent, severity, or
reversibility of perfusion defects.
In the present study, we considered the effect of
beta blockers and their withdrawal on the MPI result and
its interpretation.
The interpretation matrix of the PET studies
(Figure 3) shows that MPI results and management
recommendation were equivalent in the majority (80%),
irrespective of beta blocker intake and associated MBF
changes. In 10% the higher MBF after beta blocker
withdrawal led to mild changes in terms of a downstag-
ing, but without an essential impact on the interpretation.
To summarize, in a total of 90% of our study patients the
MPI results did not basically differ independent of beta
blocker intake, particularly in high-risk and normal MPI
patterns. Only 10% presented an essential change in study
interpretation. This subgroup needs further characteriza-
tion. The patient number of this study is, however, too
small for a deeper analysis.
NEW KNOWLEDGE GAINED
• In CAD patients, the withdrawal of a beta blocker is
associated with a significantly higher MBF under
adenosine, 8% on average.
• This MBF shift is found over the entire range of
measured MBF values.
• Heart rate is one factor of this increase, but further
interfering factors are involved.
• MPI interpretation and individual management rec-
ommendation are, in the majority of cases,
particularly in normal and high risk MPI patterns,
independent of beta blocker intake prior to the stress
test.
• In a few patients, the higher MBF without beta
blocker results in a downstaging in MPI interpretation
and management recommendation.
• Notably, there is a small CAD patient subgroup which
differs from these patterns and which needs further
investigation in a larger study cohort.
CONCLUSION
The question of whether beta blockers need to be
stopped before vasodilator stress testing cannot be
answered for a diverse CAD population with a universal
‘‘no’’ or ‘‘yes.’’ As adenosine MBF without beta blockers
is higher than with, the clinical pathway recommending
the stop of beta blockers prior to stress testing in order to
ensure the highest MBF remains advisable. However, if a
temporary beta blocker withdrawal is unfeasible due to
complications, contraindications, a tight clinical sche-
dule, or because a patient simply forgot to withhold the
medication, it is appropriate to perform adenosine stress
testing in such cases.
Study Limitations
In this study, patients with known CAD, comorbid-
ities, and cardiac co-medication were considered. The
results may not be directly transferable to low or
moderate risk groups scheduled for exclusion of CAD
with MPI.
The cardiac co-medication may have interfered with
perfusion to a different extent between both adenosine
studies. A potential bias is not assessable. By leaving the
co-medication unchanged between the studies, an
attempt was made to minimize any co-medication
effects.
The patients took a total of four different beta
blockers, three of them cardioselective. An optimal
study condition would have been with one single beta
blocker in all patients. However, 95% of the patients had
cardioselective beta blockers with comparable working
profiles. Thus, a confounding effect by the different beta
blockers is thought to be low.
The overall sample size of this studied population is
very small. Thus, it is very difficult to draw hard
conclusions from the study. The results in Figures 1 and 3
show that the withdrawal of beta blockers leads to
divergent and variable changes in MBF and thus limits its
application in clinical decision making. This also raises
the question of whether the observations seen are more
random and not systematic in nature. For all these
reasons, a larger study is clearly needed.
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